RetinalGenix Technologies Inc. Files Q1 2024 10-Q

TL;DR

RetinalGenix Q1 2024 10-Q filed. Check financials.

AI Summary

RetinalGenix Technologies Inc. filed a 10-Q for the period ending March 31, 2024. The filing details financial information and business operations. The company is located in Petaluma, CA, and its fiscal year ends on December 31.

Why It Matters

This filing provides investors with an update on RetinalGenix Technologies Inc.'s financial health and operational status for the first quarter of 2024.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new information presented in the provided snippet.

Key Numbers

• 20240331 — Reporting Period End Date (Quarterly financial reporting)
• 20240520 — Filing Date (Submission of the 10-Q)
• 1231 — Fiscal Year End (Annual financial cycle)

Key Players & Entities

• RetinalGenix Technologies Inc. (company) — Filer
• Petaluma, CA (location) — Business Address
• 1450 NORTH MCDOWELL BOULEVARD (location) — Business Address Street 1
• SUITE 150 (location) — Business Address Street 2
• 415-578-9583 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.0001 — of shares of the issuer's common stock, $0.0001 par value per share, outstanding at May
• $0.01 — F Original Issue Price" initially means $0.01 and "Series F Conversion Price" initial
• $0 — ies F Conversion Price" initially means $0.01, as adjusted for any dilutive transa

Filing Documents

• form10-q.htm (10-Q) — 498KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-24-020564.txt ( ) — 3088KB
• rtgn-20240331.xsd (EX-101.SCH) — 24KB
• rtgn-20240331_cal.xml (EX-101.CAL) — 26KB
• rtgn-20240331_def.xml (EX-101.DEF) — 122KB
• rtgn-20240331_lab.xml (EX-101.LAB) — 225KB
• rtgn-20240331_pre.xml (EX-101.PRE) — 186KB
• form10-q_htm.xml (XML) — 350KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3936890 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1450 North McDowell Boulevard , Suite 150 Petaluma , CA 94954 (Address of principal executive offices) (Zip Code) (415) 578-9583 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Act: None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The number of shares of the issuer's common stock, $0.0001 par value per share, outstanding at May 15, 2024 was 17,860,478 . PART I — FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31, 2024 December 31, 2023 ASSETS Current Assets Cash $ 50,386 $ 0 Total Current Assets 50,386 0 Equipment, net of accumulated depreciation of $ 176 and $ 151 131 156 TOTAL ASSETS $ 50,517 $ 156 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Liabilities Accounts payable and accrued liabilities 813,638 884,920 Due to Sanovas 193,360 2,760 Due to related parties 500,789 457,534 Shareholders' notes payable 49,000 49,000 Accrued interest payable 12,559 11,559 Total Liabilities 1,569,346 1,405,813 Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at December 31, 2023 and March 31, 2024 - - Common stock, $ 0.0001 par value; 80,000,000 shares authorized; 17,860,478 and 17,635,478 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 1,786 1,764 Additional paid in capital 11,734,456 9,701,774 Accumulated deficit ( 13,255,071 ) ( 11,109,195 ) Total Stockholders' Deficit ( 1,518,829 ) ( 1,405,657 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 50,517 $ 156 The accompanying notes are an integral part of these consolidated financial statements. 2 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED 2024 2023 For The Year Quarter Ended March 31, 2024 2023 Revenues $ - $ - Operating expenses: General and administrative expenses 328,985 203,242 Research and development 83,097 227,932 Stock-based compensation 1,732,834 78,509 Total Operating expenses 2,144,916 509,683 Interest expense 960 960 Net loss $ ( 2,145,876 ) $ ( 510,643 ) Net loss per share - basic and diluted $ ( 0.12 ) $ ( 0.03 ) Weighted average number of common shares outstanding during the period- basic and diluted 17,672,145 17,272,116 The accompanying notes are an integral part of these consolidated financial statements. 3 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 Shares Par Value Additional paid in capital Accumulated Deficit Total stockholders' deficit Balance as at December 31, 2022

View Full Filing

View this 10-Q filing on SEC EDGAR